

Newsletter from Emotra AB (publ)
Göteborg, January 14, 2016

A short update from Emotra – Presentation in Sao Paolo

Lars-Håkan Thorell, the inventor of EDOR, has been invited to be one of the keynote speakers at a large conference on bipolar disorders being held in Sao Paulo, Brazil, on August 22–23, 2016. At this conference he will present EDOR and the research behind the method, as well as the ongoing European clinical multi-centre study. Dr Thorell and professor Sarchiapone will also be presenting EDOR at several other international gatherings during the year.

Dr Lars-Håkan Thorell, the researcher and inventor of EDOR and today Emotra's Head of Research, has been invited to be one of the keynote speakers at the international Bipolar Disorders conference being held in Sao Paulo, Brazil on August 22–23, 2016. He has accepted this invitation and will be holding the presentation they have requested. Studies have shown that suicide risk is especially high among patients who have been diagnosed with bipolar disorders. Earlier studies using EDOR to assess suicide risk have shown that bipolar patients have an increased tendency for hyporeactivity, which is an observation that is in accordance with our knowledge of this group's high suicide risk. These observations are probably an important reason for Dr Thorell's invitation to be one of the keynote speakers at the Sao Paolo conference.

EDOR will be the subject of a number of other presentations this year, by both Lars-Håkan Thorell and by Emotra's scientific advisor, professor Marco Sarchiapone, of Molise, Italy. Among other events, they will both be holding speeches at two different conferences that are being held in Spain this year, one in Madrid in March and one in Oviedo in September. They will also be giving presentations at various national psychiatry conferences, mainly in Europe.

The European multi-centre study on the use of EDOR for assessing suicide risk, which Emotra is conducting in close collaboration with the European Psychiatric Association's Suicide Section, EPA-SS, is proceeding according to plan. So far, more than 1,300 patients' test data have been reported to Emotra for analysis. According to the people in charge of the study's calculations, we should be finished testing new patients by the end of February.

In connection with the important international conferences in Madrid in March and Oviedo in September, Emotra will be arranging follow-up meetings with the clinics involved in the study. The Company's other preparations for our planned international product launch are proceeding according to plan.

For further information, please contact: *Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: claes@emotra.se*

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.